Effective Drug Regulation - A Multicountry Study and Annex 1: Guide for Data Collection to Assess Drug Regulatory Performance
(2002; 187 pages) Ver el documento en el formato PDF
Índice de contenido
Ver el documentoACRONYMS
Ver el documentoPREFACE
Ver el documentoACKNOWLEDGEMENTS
Ver el documentoEXECUTIVE SUMMARY
Abrir esta carpeta y ver su contenido1. DRUG REGULATION: OBJECTIVES AND ISSUES
Abrir esta carpeta y ver su contenido2. MULTICOUNTRY STUDY ON EFFECTIVE DRUG REGULATION
Abrir esta carpeta y ver su contenido3. PROFILE OF THE COUNTRIES
Abrir esta carpeta y ver su contenido4. REGULATORY FRAMEWORK
Abrir esta carpeta y ver su contenido5. REGULATORY CAPACITY
Abrir esta carpeta y ver su contenido6. LICENSING OF MANUFACTURING, DISTRIBUTION AND RETAIL SALE
Abrir esta carpeta y ver su contenido7. INSPECTION AND SURVEILLANCE
Abrir esta carpeta y ver su contenido8. PRODUCT ASSESSMENT AND REGISTRATION
Abrir esta carpeta y ver su contenido9. CONTROL OF DRUG PROMOTION AND ADVERTISING
Abrir esta carpeta y ver su contenido10. DRUG QUALITY CONTROL LABORATORY
Abrir esta carpeta y ver su contenido11. ASSESSING REGULATORY PERFORMANCE
Abrir esta carpeta y ver su contenido12. CONCLUSIONS AND RECOMMENDATIONS FOR EFFECTIVE DRUG REGULATION
Cerrar esta carpetaANNEX 1: GUIDE FOR DATA COLLECTION TO ASSESS DRUG REGULATORY PERFORMANCE
Ver el documento1. Background information
Ver el documento2. Drug regulation: overview
Cerrar esta carpeta3. Regulatory functions
Ver el documento3.1 Licensing: persons, premises and practices
Abrir esta carpeta y ver su contenido3.2 Inspection and surveillance
Ver el documento3.3 Product assessment and registration
Ver el documento3.4 Adverse drug reaction monitoring
Ver el documento3.5 Clinical trials
Ver el documento3.6 Control of drug promotion and advertising
Ver el documento3.7 Drug quality control laboratory
 

3.6 Control of drug promotion and advertising

PA1: Is there legal provision for the control of drug promotion and advertising?

Yes
No

PA1.1: If yes, indicate the title, date of enactment and article number of the legislation/regulations:

________________________________________________________________

PA2: State any restrictions specified in the law on drug promotion and advertising:

________________________________________________________________

PA3: Are prescription drugs advertised:

 

Yes/No

In the lay press?

 

In health professional journals?

 

On radio and television?

 

On billboards?

 

PA4: Which body controls drug advertising/promotion?

________________________________________________________________

PA5: Is pre-approval required for promotional and advertising materials?

Yes
No

PA5.1: If yes, what body issues the pre-approval?

________________________________________________________________

PA5.2: Is there a fee for pre-approval?

Yes
No

PA5.3: If no, how is drug advertising/promotion monitored?

________________________________________________________________

PA6: Is a product information sheet/summary of product characteristics approved at the time of registration?

Yes
No

PA6.1: Are patient information leaflets and labels subject to approval?

Yes
No

PA7: Are there sanctions for violations of laws on product information and promotion?

Yes
No

PA7.1: How many violations have been registered and administrative measures and legal sanctions taken in the last five years?

Violations and enforcement measures taken

Year:

Year:

Year:

Year:

Year:

Number of violations of drug promotion law/regulations registered

         

Number of judicial sanctions implemented

         

Number of administrative measures taken

         

PA7.2: Are sanctions effective?

Yes
No

PI8: Is/are there association(s) of pharmaceutical manufacturers/companies that practise self-regulation?

Yes
No

PI8.1: If yes, indicate the name(s) of the association(s), obtain copies of the code of practice, and provide information on the extent to which they are effective:

________________________________________________________________

PA9: Does the drug regulatory authority provide independent drug information to prescribers, dispensers and the public?

Yes
No

PA9.1: If yes, obtain a copy the latest publication.

PA9.2: If no, does any other body provide information independent of the industry?

Yes
No

PA9.3: If yes, indicate the name (s) of such bodies:

________________________________________________________________

PA10: How are the public and prescribers informed about newly registered drugs? Explain:

________________________________________________________________

PA11: Is there a mechanism whereby false medical claims in advertisements are controlled? If yes, explain.

Yes
No

PA12: What are the main constraints, weaknesses or problems and the strengths of control of drug promotion/advertising?

Constraints/weaknesses/problems

Strengths

   
   

Indicators

1. Number of advertisements/promotions found to be in violation of the law, out of the total number of promotions/advertisements monitored (indicate year).

2. Number of labels/inserts found to be inconsistent with what was approved during registration, out of the total number of labels and inserts assessed (indicate year).

3. Number of product information documents found to be in inappropriate language, out of the total number of product information documents assessed (indicate year).

If there is any specific and important information that is not covered by the above questions, please provide additional information as appropriate.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013